Global Pruritus therapeutics market is expected to reach USD 13.83 billion by 2022, growing at a CAGR of 4.8% between 2016 and 2022.
The report covers forecast and analysis for the pruritus therapeutics market on a global and regional level. The study provides historic data of 2014 and 2015 along with a forecast from 2016 to 2022 based on revenue (USD Billion). The study includes drivers and restraints for the pruritus therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Pruritus therapeutics market on a global level.
This report offers comprehensive coverage on global pruritus therapeutics market along with, market trends, drivers, and restraints of Pruritus therapeutics market. This report includes a detailed competitive scenario and technology portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the pruritus therapeutics market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared by using data sourced from in-house databases, secondary and primary research team of industry experts. Research analysts and consultants cooperate with leading companies of the concerned domain to verify every value of data exists in this report.
The study provides a decisive view on the pruritus therapeutics market by segmenting the market based on therapeutic type and regions. All these segments have been analyzed based on present and future trends and the market is estimated from 2014 to 2022. The therapeutic type based market covered under this study includes antihistamines, topical corticosteroids, opioid receptor antagonists, topical immunomodulators, antidepressants, immunosuppressants, topical local anesthetics, cannabinoid receptors and others. This report also includes the current and forecast demand for the region of North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa.
Key operating players in pruritus therapeutics market are like Brunswick Corporation, Johnson Health Tech Co. Ltd., Nautilus Strength, Icon Health & Fitness, Amer Sports, Technogym, Precor incorporated and Cybex International Inc.
This report segments the pruritus therapeutics market as follows:
Global Pruritus Therapeutics Market: Therapeutic Type Analysis
Global Pruritus Therapeutics Market: Regional Analysis
This report is based on in-depth qualitative and quantitative analyses of the global Pruritus Therapeutics market. Zion Research has collected and analyzed key data belong to the global Pruritus Therapeutics market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.
The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.
Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Pruritus Therapeutics across the world has been calculated through primary and secondary research.
Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc.
For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Pruritus Therapeutics industry. Primary research makes up the major source of data collection and validation.
We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:
Participants who typically participate in such a process include, but are not limited to:
Key opinion leaders specializing in different areas corresponding to different industry verticals
Secondary research sources that are typically referred to include, but are not limited to:
News articles, press releases and webcasts specific to companies operating in the market
Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Pruritus Therapeutics market.
Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:
Pruritus is the medical term for itchy skin. Pruritus is the most common dermatological disorder. Pruritus is a normal body reaction to protect from harmful external parasites or substances such as insect bites. However, it can be as a result of wide range of skin diseases. Pruritus lasting for more than 6 weeks is called chronic pruritus. Pruritus has been classified into the following four key types include neuropathic, cutaneous, psychogenic and neurogenic. Chronic renal failure is a vital cause of persistent pruritus. Pruritus is enhanced or provoked by a number of chemical substances such as prostaglandins, cytokines, histamine, proteases, neuropeptides and bile salts. Furthermore, chronic pruritus is becoming a burden to society mainly due to the treatment-related costs, which is particularly high due to the elevation rate of therapeutic failure.
Atopic dermatitis is also known as eczema. This is one of the most common skin diseases found in children. Itching may cause skin darkening & thickening and lead to further complications including bacterial infection. In atopic dermatitis, the primary skin becomes extremely inflamed & itchy causing swelling, redness, vesicle formation, cracking, crusting, weeping, and scaling. Thus, pruritus therapeutics market is mainly driven by increasing the prevalence of atopic dermatitis. Moreover, development of new drug and a strong pipeline is also expected to propel the market growth in the years. However, lack of awareness about pruritus may hamper the growth of pruritus therapeutics market. Nonetheless, untapped market and an increasing number of patent expiry of pruritus drugs may generate new opportunity in the forecast period.
The market of pruritus therapeutics has been segmented into antihistamines, topical corticosteroids, opioid receptor antagonists, topical immunomodulators, antidepressants, immunosuppressants, topical local anesthetics, cannabinoid receptors and others. Topical corticosteroids segment dominated the market with more than 20% market share in 2014 while antidepressants segment expected to witness exponential growth in the forecast period. Topical corticosteroids are mostly used to provide relief of itching associated with inflammatory skin diseases such as atopic dermatitis or psoriasis.
Based on region, the pruritus therapeutics market is classified into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. As a result of favorable government initiatives and introduction of new products for pruritus treatments, North America dominated the market in 2014. Europe was the second largest segment in pruritus therapeutics market and is projected to grow at a steady growth rate.
Key players operating in the global pruritus therapeutics market include Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical Industries Ltd., Ajanta Pharma ltd, Abbot Lab, GSK and Galderma.